25,000 Shares in Alumis Inc. (NASDAQ:ALMS) Bought by Maven Securities LTD

Maven Securities LTD purchased a new stake in Alumis Inc. (NASDAQ:ALMS) during the 2nd quarter, Holdings Channel reports. The firm purchased 25,000 shares of the company’s stock, valued at approximately $332,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Millennium Management LLC bought a new position in shares of Alumis in the 2nd quarter valued at about $3,376,000. Towerview LLC acquired a new position in Alumis during the second quarter valued at approximately $4,123,000. Ally Bridge Group NY LLC bought a new position in Alumis in the second quarter valued at approximately $8,229,000. Yu Fan acquired a new position in shares of Alumis during the 2nd quarter worth approximately $10,502,000. Finally, SR One Capital Management LP bought a new stake in shares of Alumis during the 2nd quarter worth approximately $26,067,000.

Alumis Stock Down 2.5 %

Shares of ALMS stock opened at $10.40 on Thursday. Alumis Inc. has a 52 week low of $10.30 and a 52 week high of $13.53. The business’s 50-day moving average is $12.06.

Alumis (NASDAQ:ALMS) last posted its earnings results on Tuesday, August 13th. The company reported ($23.10) EPS for the quarter, missing the consensus estimate of ($1.57) by ($21.53). On average, research analysts forecast that Alumis Inc. will post -6.86 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Morgan Stanley began coverage on shares of Alumis in a research note on Tuesday, July 23rd. They issued an “overweight” rating and a $36.00 target price for the company. Guggenheim assumed coverage on shares of Alumis in a research note on Tuesday, July 23rd. They set a “buy” rating and a $32.00 price objective on the stock. Leerink Partners assumed coverage on shares of Alumis in a research note on Tuesday, July 23rd. They issued an “outperform” rating and a $29.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a research report on Monday, August 19th. Finally, Leerink Partnrs raised Alumis to a “strong-buy” rating in a research report on Tuesday, July 23rd. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $27.50.

Alumis Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.